Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Bristol-Myers Squibb Co's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 63.85.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bristol-Myers Squibb Co's liquidation value for the
three
months ended in Jun. 2026 was $-46,072 Mil.
Bristol-Myers Squibb Co (NYSE:BMY) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Bristol-Myers Squibb Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Change In Receivables Related Terms
Bristol-Myers Squibb Co Change In Receivables Historical Data
* Premium members only.
The historical data trend for Bristol-Myers Squibb Co's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Change In Receivables Chart
Bristol-Myers Squibb Co Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $678 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of $678 Mil mean?
Bristol-Myers Squibb Co (BMY) has a Change In Receivables of $678 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Change In Receivables too high?
Bristol-Myers Squibb Co's current Change In Receivables is $678 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Change In Receivables compare to PFE and GILD?
Bristol-Myers Squibb Co's Change In Receivables of $678 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Change In Receivables is $678 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $56.04, compared to a current price of $65.31 — trading 16.5% above its estimated fair value. The current Change In Receivables is $678 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BMY), the current Change In Receivables is $678 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $65.31 is trading 16.5% above its estimated GF Value™ of $56.04.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for BMY:
Change In Receivables: $678 Mil
GF Value™: $56.04 vs. price of $65.31 (16.5% above fair value)
No single metric tells the full story. See the BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score
Get the complete analysis for BMY
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMY has been successfully added to your 
